Authors:
LEMM G
KUPPERS J
FREY R
WINGENDER W
KUHLMANN J
Citation: G. Lemm et al., MONITORING OF PROTEINURIA IN PHASE-I STUDIES IN HEALTHY MALE-SUBJECTS, European Journal of Clinical Pharmacology, 54(4), 1998, pp. 287-294
Authors:
MUCK W
RITTER W
OCHMANN K
UNGER S
AHR G
WINGENDER W
KUHLMANN J
Citation: W. Muck et al., ABSOLUTE AND RELATIVE BIOAVAILABILITY OF THE HMG-COA REDUCTASE INHIBITOR CERIVASTATIN, International journal of clinical pharmacology and therapeutics, 35(6), 1997, pp. 255-260
Authors:
DIETRICH H
RITTER W
WINGENDER W
UNGER S
OCHMANN K
Citation: H. Dietrich et al., CERIVASTATIN - A NEW HMG-COA REDUCTASE INHIBITOR - IN COMBINATION WITH THE ANTACID MAALOX(R) - AN INVESTIGATION OF THE SAFETY AND PHARMACOKINETICS, Atherosclerosis, 130, 1997, pp. 101-101
Authors:
FREY R
RITTER W
UNGER S
OCHMANN K
WINGENDER W
Citation: R. Frey et al., PHASE-I STUDY TO INVESTIGATE THE EFFECTS OF CIMETIDINE ON THE PHARMACOKINETICS OF CERIVASTATIN - A NEW HMG-COA REDUCTASE INHIBITOR, Atherosclerosis, 130, 1997, pp. 103-103